MedCAC To Examine ESAs In Chronic Kidney Disease, Pharmacogenomic Testing In Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The usage of erythropoiesis stimulating agents outside the renal setting is already subject to coverage limitations in Medicare.
You may also be interested in...
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Data suggesting some link between CYP2C9 or VKORC1 gene mutations and a patient's likelihood of fatal excessive bleeding in response to the drug are enough for a coverage-with-evidence-development policy, where beneficiaries enrolled in qualifying trials are covered.